Format

Send to

Choose Destination
Eur J Cancer. 2014 Jul;50(11):1909-15. doi: 10.1016/j.ejca.2014.04.008. Epub 2014 May 21.

A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer.

Author information

1
British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada. Electronic address: drenouf@bccancer.bc.ca.
2
Tom Baker Cancer Centre, Calgary, AB, Canada.
3
University Health Network-Princess Margaret Cancer Centre, Toronto, ON, Canada.
4
British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada.
5
Cross Cancer Institute, Edmonton, AB, Canada.

Abstract

BACKGROUND:

Erlotinib induced skin toxicity has been associated with clinical benefit in several tumour types. This phase II study evaluated the efficacy of erlotinib, dose escalated to rash, in patients with advanced pancreatic cancer previously treated with gemcitabine.

METHODS:

Erlotinib was given at an initial dose of 150 mg/day, and the dose was escalated by 50mg every 2 weeks (to a maximum of 300 mg/day) until >grade 1 rash or other dose limiting toxicities occurred. Erlotinib pharmacokinetics were performed, and baseline tumour tissue was collected for mutational analysis and epidermal growth factor receptor (EGFR) expression. The primary end-point was the disease control rate (objective response and stable disease >8 weeks).

RESULTS:

Fifty-one patients were accrued, and 49 received treatment. Dose-escalation to 200-300 mg of erlotinib was possible in 9/49 (18%) patients. The most common ⩾ grade 3 adverse events included fatigue (6%), rash (4%) and diarrhoea (4%). Thirty-seven patients were evaluable for response, and the best response was stable disease in 12 patients (32% (95% confidence interval (CI) 17-47%)). Disease control was observed in nine patients (24% (95% CI: 10-38%)). Median survival was 3.8 months, and 6 month overall survival rate was 32% (95% CI 19-47%). Mutational analysis and EGFR expression were performed on 29 patients, with 93% having KRAS mutations, none having EGFR mutations, and 86% expressing EGFR. Neither KRAS mutational status nor EGFR expression was associated with survival.

CONCLUSIONS:

Erlotinib dose escalated to rash was well tolerated but not associated with significant efficacy in non-selected patients with advanced pancreatic cancer.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00497224.

KEYWORDS:

Erlotinib; Pancreatic cancer; Phase II

PMID:
24857345
DOI:
10.1016/j.ejca.2014.04.008
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center